🧬 Tirzepatide Peptide (10 mg or 20mg)
Dual GIP / GLP‑1 Receptor Agonist for Advanced Metabolic Research in Canada
Tirzepatide peptide is a high‑purity, synthetic dual‑agonist research compound studied in laboratory settings for its interaction with GIP (glucose‑dependent insulinotropic polypeptide) and GLP‑1 (glucagon‑like peptide‑1) receptor pathways. Its unique ability to engage two incretin receptor systems simultaneously makes it a valuable tool in advanced metabolic and signaling research.
Supplied by BlueNexLabs, Tirzepatide is provided as a lyophilized research peptide (10 mg or 20mg) with COA‑verified purity, optimized for Canadian research laboratories requiring audit‑safe RUO reagents.
🔬 Overview of Tirzepatide in Research Settings
Tirzepatide is designed as a synthetic peptide analog that enables controlled investigation of multi‑receptor incretin signaling in in‑vitro and preclinical research models. By activating both GIPR and GLP‑1R, it supports experimental exploration of how coordinated receptor engagement influences:
Metabolic signal integration
Energy‑regulation pathways
Receptor bias and signaling efficiency
Peptide structure–function relationships
Because of its dual‑agonist architecture, Tirzepatide is frequently used as a model compound in studies examining multi‑pathway peptide mechanisms and receptor crosstalk.
🧪 Research Applications (Non‑Medical)
Tirzepatide is intended strictly for laboratory research use and is commonly applied in:
Dual‑receptor binding studies
Comparative analysis of GIPR vs. GLP‑1R affinity, receptor selectivity, and downstream signal strength.
cAMP & intracellular signaling assays
Modeling PKA‑linked transcription, CREB phosphorylation, and incretin‑linked signal cascades.
Peptide–receptor kinetics research
Assays focused on receptor internalization, β‑arrestin recruitment, and recycling behavior.
Structure–function & stability studies
Evaluating how fatty‑acid conjugation and sequence modifications affect stability, albumin association, and receptor engagement in vitro.
Analytical & method development
Suitable for HPLC / UPLC / MS method validation involving long‑chain, lipidated peptides.
All applications remain non‑clinical and research‑only.
🧬 Molecular & Chemical Characteristics
Type: Synthetic dual‑agonist peptide (GIPR + GLP‑1R)
Form: Lyophilized peptide powder
Size: 10 mg vial
Identity Verification: Mass Spectrometry (MS)
Purity Analysis: HPLC / UPLC
Structural Features
Sequence‑level substitutions designed to improve enzymatic stability
Fatty‑acid side chain enabling albumin interaction in vitro
Demonstrates dual‑receptor engagement with measurable receptor bias
Biochemical Behavior
Solubility dependent on pH, buffer system, and ionic strength
Lipidated peptides may aggregate if improperly prepared
Sensitive to oxidation and hydrolysis post‑reconstitution
Store lyophilized peptide at –20 °C, protected from light and moisture
Reconstituted solutions: 2–8 °C, short‑term research use only
Avoid repeated freeze–thaw cycles
Aliquot after reconstitution if required
Use low‑binding laboratory consumables to reduce peptide adsorption
Each batch of Tirzepatide supplied by BlueNexLabs includes audit‑ready documentation, consisting of:
🔗 View Certificate of Analysis (COA)
🔗 Learn About Our Testing Standards
🔗 Explore the BlueNexLabs Research Peptide Catalog
🇨🇦 Supplied for Canadian Research Laboratories
BlueNexLabs provides Tirzepatide research peptide to laboratories across Canada, including:
Vancouver • Toronto • Montreal • Calgary • Edmonton • Ottawa • Nationwide
Why Researchers Choose BlueNexLabs
⚠️ Compliance Notice
This product is supplied strictly for laboratory research use only (RUO).
Not for human or veterinary use.
No medical, therapeutic, diagnostic, or performance‑related claims are made or implied.
🧬 Tirzepatide Peptide (10 mg or 20mg)
Dual GIP / GLP‑1 Receptor Agonist for Advanced Metabolic Research in Canada
Tirzepatide peptide is a high‑purity, synthetic dual‑agonist research compound studied in laboratory settings for its interaction with GIP (glucose‑dependent insulinotropic polypeptide) and GLP‑1 (glucagon‑like peptide‑1) receptor pathways. Its unique ability to engage two incretin receptor systems simultaneously makes it a valuable tool in advanced metabolic and signaling research.
Supplied by BlueNexLabs, Tirzepatide is provided as a lyophilized research peptide (10 mg or 20mg) with COA‑verified purity, optimized for Canadian research laboratories requiring audit‑safe RUO reagents.
🔬 Overview of Tirzepatide in Research Settings
Tirzepatide is designed as a synthetic peptide analog that enables controlled investigation of multi‑receptor incretin signaling in in‑vitro and preclinical research models. By activating both GIPR and GLP‑1R, it supports experimental exploration of how coordinated receptor engagement influences:
Metabolic signal integration
Energy‑regulation pathways
Receptor bias and signaling efficiency
Peptide structure–function relationships
Because of its dual‑agonist architecture, Tirzepatide is frequently used as a model compound in studies examining multi‑pathway peptide mechanisms and receptor crosstalk.
🧪 Research Applications (Non‑Medical)
Tirzepatide is intended strictly for laboratory research use and is commonly applied in:
Dual‑receptor binding studies
Comparative analysis of GIPR vs. GLP‑1R affinity, receptor selectivity, and downstream signal strength.
cAMP & intracellular signaling assays
Modeling PKA‑linked transcription, CREB phosphorylation, and incretin‑linked signal cascades.
Peptide–receptor kinetics research
Assays focused on receptor internalization, β‑arrestin recruitment, and recycling behavior.
Structure–function & stability studies
Evaluating how fatty‑acid conjugation and sequence modifications affect stability, albumin association, and receptor engagement in vitro.
Analytical & method development
Suitable for HPLC / UPLC / MS method validation involving long‑chain, lipidated peptides.
All applications remain non‑clinical and research‑only.
🧬 Molecular & Chemical Characteristics
Type: Synthetic dual‑agonist peptide (GIPR + GLP‑1R)
Form: Lyophilized peptide powder
Size: 10 mg vial
Identity Verification: Mass Spectrometry (MS)
Purity Analysis: HPLC / UPLC
Structural Features
Sequence‑level substitutions designed to improve enzymatic stability
Fatty‑acid side chain enabling albumin interaction in vitro
Demonstrates dual‑receptor engagement with measurable receptor bias
Biochemical Behavior
Solubility dependent on pH, buffer system, and ionic strength
Lipidated peptides may aggregate if improperly prepared
Sensitive to oxidation and hydrolysis post‑reconstitution
Store lyophilized peptide at –20 °C, protected from light and moisture
Reconstituted solutions: 2–8 °C, short‑term research use only
Avoid repeated freeze–thaw cycles
Aliquot after reconstitution if required
Use low‑binding laboratory consumables to reduce peptide adsorption
Each batch of Tirzepatide supplied by BlueNexLabs includes audit‑ready documentation, consisting of:
🔗 View Certificate of Analysis (COA)
🔗 Learn About Our Testing Standards
🔗 Explore the BlueNexLabs Research Peptide Catalog
🇨🇦 Supplied for Canadian Research Laboratories
BlueNexLabs provides Tirzepatide research peptide to laboratories across Canada, including:
Vancouver • Toronto • Montreal • Calgary • Edmonton • Ottawa • Nationwide
Why Researchers Choose BlueNexLabs
⚠️ Compliance Notice
This product is supplied strictly for laboratory research use only (RUO).
Not for human or veterinary use.
No medical, therapeutic, diagnostic, or performance‑related claims are made or implied.
